Lucira Files for Authorization of COVID-19 & Flu At-Home Molecular Test

 Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of innovative infectious disease tests, announced today that it has submitted a request to the U.S. Food and Drug Administration for emergency use authorization (EUA) for its COVID-19 & Flu test. The request is for prescription at-home use of the PCR-quality test for those with suspected COVID-19 or Influenza. Lucira is seeking FDA authorization before this upcoming fall and winter, when SARS-CoV-2 and influenza viruses are likely to co-circulate.

https://www.globenewswire.com/news-release/2022/05/12/2441746/0/en/Lucira-Files-for-Authorization-of-First-of-its-Kind-COVID-19-Flu-At-Home-Molecular-Test.html